[go: up one dir, main page]

BR9711027A - Derivados de cido hidrox mico e carboxilico tendo atividade inibora de mmp e tnf - Google Patents

Derivados de cido hidrox mico e carboxilico tendo atividade inibora de mmp e tnf

Info

Publication number
BR9711027A
BR9711027A BR9711027A BR9711027A BR9711027A BR 9711027 A BR9711027 A BR 9711027A BR 9711027 A BR9711027 A BR 9711027A BR 9711027 A BR9711027 A BR 9711027A BR 9711027 A BR9711027 A BR 9711027A
Authority
BR
Brazil
Prior art keywords
carboxylic acid
acid derivatives
hydroxic
mmp
inhibitory activity
Prior art date
Application number
BR9711027A
Other languages
English (en)
Inventor
David Alan Owen
John Gary Montana
John Fraser Keily
Robert John Watson
Andrew Douglas Baxter
Original Assignee
Darwin Discovery Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9616599.8A external-priority patent/GB9616599D0/en
Priority claimed from GBGB9707427.2A external-priority patent/GB9707427D0/en
Application filed by Darwin Discovery Ltd filed Critical Darwin Discovery Ltd
Publication of BR9711027A publication Critical patent/BR9711027A/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00Sulfones; Sulfoxides
    • C07C317/44Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Quinoline Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Indole Compounds (AREA)
BR9711027A 1996-08-07 1997-08-07 Derivados de cido hidrox mico e carboxilico tendo atividade inibora de mmp e tnf BR9711027A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9616599.8A GB9616599D0 (en) 1996-08-07 1996-08-07 Compounds
GBGB9707427.2A GB9707427D0 (en) 1997-04-11 1997-04-11 Compounds having mmp and tnf inhibitory activity
PCT/GB1997/002129 WO1998005635A1 (en) 1996-08-07 1997-08-07 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Publications (1)

Publication Number Publication Date
BR9711027A true BR9711027A (pt) 1999-08-17

Family

ID=26309836

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9711027A BR9711027A (pt) 1996-08-07 1997-08-07 Derivados de cido hidrox mico e carboxilico tendo atividade inibora de mmp e tnf

Country Status (17)

Country Link
US (1) US6118001A (pt)
EP (1) EP0968182B1 (pt)
JP (1) JP2000517297A (pt)
KR (1) KR20000029858A (pt)
CN (1) CN1227540A (pt)
AT (1) ATE266000T1 (pt)
AU (1) AU730464B2 (pt)
BR (1) BR9711027A (pt)
CA (1) CA2263154A1 (pt)
CZ (1) CZ297278B6 (pt)
DE (1) DE69729007T2 (pt)
DK (1) DK0968182T3 (pt)
ES (1) ES2217425T3 (pt)
NO (1) NO314452B1 (pt)
PL (1) PL193829B1 (pt)
PT (1) PT968182E (pt)
WO (1) WO1998005635A1 (pt)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69829648T2 (de) * 1997-01-22 2009-12-10 Aventis Pharmaceuticals Inc. Substituierte β-Thiocarbonsäure
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
US6794511B2 (en) * 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US7115632B1 (en) 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US6380258B2 (en) * 1997-03-04 2002-04-30 G. D. Searle, L.L.C. Sulfonyl divalent aryl or heteroaryl hydroxamic acid compounds
AUPO721997A0 (en) * 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
US20030166687A1 (en) 1997-11-21 2003-09-04 Warpehoski Martha A. Alpha-hydroxy,-amino and -fluoro derivatives of beta-sulphonyl hydroxamic acids as matrix metalloproteinases inhibitors
DE69939190D1 (de) 1998-06-18 2008-09-04 Hoffmann La Roche Verfahren für Arylalkylsulfid
FR2780402B1 (fr) * 1998-06-30 2001-04-27 Adir Nouveaux composes acides carboxyliques et hydroxamiques inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2000012477A1 (en) * 1998-08-29 2000-03-09 British Biotech Pharmaceuticals Limited Hydroxamic acid derivatives as proteinase inhibitors
GB9919776D0 (en) * 1998-08-31 1999-10-27 Zeneca Ltd Compoujnds
US6858598B1 (en) 1998-12-23 2005-02-22 G. D. Searle & Co. Method of using a matrix metalloproteinase inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
GB9911073D0 (en) * 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
GB9911075D0 (en) * 1999-05-12 1999-07-14 Darwin Discovery Ltd HYdroxamic and carboxylic acid derivatives
GB9916562D0 (en) * 1999-07-14 1999-09-15 Pharmacia & Upjohn Spa 3-Arylsulfonyl-2-(substituted-methyl) propanoic acid derivatives as matrix metalloproteinase inhibitora
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
US6667316B1 (en) * 1999-11-12 2003-12-23 Celgene Corporation Pharmaceutically active isoindoline derivatives
MXPA02008112A (es) * 2000-02-21 2002-11-29 Astrazeneca Ab Arilpiperazinas y arilpiperidinas y su uso agentes inhibidores de metaloproteinasa.
GB0009760D0 (en) 2000-04-19 2000-06-07 Oxford Biomedica Ltd Method
JP2003533521A (ja) 2000-05-15 2003-11-11 ダーウィン・ディスカバリー・リミテッド ヒドロキサム酸誘導体
US6506773B2 (en) 2000-05-15 2003-01-14 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives
US6469020B2 (en) 2000-05-15 2002-10-22 Darwin Discovery, Ltd. Hydroxamic and carboxylic acid derivatives
GB0020498D0 (en) 2000-08-18 2000-10-11 Sterix Ltd Compound
US7842727B2 (en) 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
CA2344208A1 (en) 2001-04-30 2002-10-30 Oxford Biomedica (Uk) Limited Method
GB0119474D0 (en) 2001-08-09 2001-10-03 Astrazeneca Ab Compounds
AU2003243272A1 (en) 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
AU2003247390A1 (en) * 2002-05-22 2003-12-12 Errant Gene Therapeutics, Llc. Histone deacetylase inhibitors based on alphachalcogenmethylcarbonyl compounds
DE10226370B4 (de) 2002-06-13 2008-12-11 Polyic Gmbh & Co. Kg Substrat für ein elektronisches Bauteil, Verwendung des Substrates, Verfahren zur Erhöhung der Ladungsträgermobilität und Organischer Feld-Effekt Transistor (OFET)
DE10233085B4 (de) 2002-07-19 2014-02-20 Dendron Gmbh Stent mit Führungsdraht
US8425549B2 (en) 2002-07-23 2013-04-23 Reverse Medical Corporation Systems and methods for removing obstructive matter from body lumens and treating vascular defects
AU2003261319A1 (en) 2002-08-01 2004-02-23 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme
JP2006516548A (ja) 2002-12-30 2006-07-06 アンジオテック インターナショナル アクツィエン ゲゼルシャフト 迅速ゲル化ポリマー組成物からの薬物送達法
GB0411562D0 (en) 2004-05-24 2004-06-23 Sterix Ltd Compound
GB0412492D0 (en) 2004-06-04 2004-07-07 Sterix Ltd Compound
US20050277897A1 (en) * 2004-06-14 2005-12-15 Ghannoum Ziad R Handpiece tip
KR20080002866A (ko) * 2005-04-25 2008-01-04 노파르티스 아게 펩티드 데포르밀라제 (pdf) 억제제로서 유용한이미다조(1,2-a)피리딘 유도체
DE102005019181A1 (de) * 2005-04-25 2006-10-26 Novartis Ag Peptid-Deformylase (PDF) Inhibitoren 1
PL2002003T3 (pl) 2005-05-27 2016-06-30 Ospedale San Raffaele Srl Wektor genetyczny zawierający mi-RNA
GB0513702D0 (en) 2005-07-04 2005-08-10 Sterix Ltd Compound
GB0526210D0 (en) 2005-12-22 2006-02-01 Oxford Biomedica Ltd Vectors
GB0604142D0 (en) 2006-03-01 2006-04-12 Sterix Ltd Compound
ATE509956T1 (de) * 2006-06-08 2011-06-15 Helmholtz Zentrum Muenchen Spezifische proteaseinhibitoren und ihre verwendung in der krebstherapie
JP2010504281A (ja) * 2006-07-27 2010-02-12 エミスフェアー・テクノロジーズ・インク アリールスルファニル化合物、および活性薬剤を送達するための組成物
GB0706072D0 (en) 2007-03-28 2007-05-09 Sterix Ltd Compound
US8088140B2 (en) 2008-05-19 2012-01-03 Mindframe, Inc. Blood flow restorative and embolus removal methods
US11337714B2 (en) 2007-10-17 2022-05-24 Covidien Lp Restoring blood flow and clot removal during acute ischemic stroke
GB0722779D0 (en) 2007-11-20 2008-01-02 Sterix Ltd Compound
KR101819554B1 (ko) 2008-02-22 2018-01-17 마이크로 테라퓨틱스 인코포레이티드 혈류를 회복하는 방법 및 기구
EP3192874B1 (en) 2008-06-18 2019-10-16 Oxford BioMedica (UK) Limited Virus purification
EP2364362B1 (en) 2008-11-12 2015-10-21 Ospedale San Raffaele S.r.l. Gene vector for inducing transgene-specific immune tolerance
EP2424571B1 (en) 2009-04-30 2020-04-08 Ospedale San Raffaele S.r.l. Gene vector
GB0914767D0 (en) 2009-08-24 2009-09-30 Sterix Ltd Compound
US9039749B2 (en) 2010-10-01 2015-05-26 Covidien Lp Methods and apparatuses for flow restoration and implanting members in the human body
WO2012156839A2 (en) 2011-05-19 2012-11-22 Ospedale San Raffaele S.R.L. New generation of splice-less lentiviral vectors for safer gene therapy applications
EP2953932B1 (en) 2013-02-06 2017-03-01 Merck Patent GmbH Substituted carboxylic acid derivatives as aggrecanase inhibitors for the treatment of osteoarthritis
EP2968568A2 (en) 2013-03-11 2016-01-20 Life Science Nutrition AS Natural lipids containing non-oxidizable fatty acids
US10076399B2 (en) 2013-09-13 2018-09-18 Covidien Lp Endovascular device engagement
ES2747951T3 (es) 2013-10-24 2020-03-12 Ospedale San Raffaele Srl Método
GB201322798D0 (en) 2013-12-20 2014-02-05 Oxford Biomedica Ltd Production system
GB201407322D0 (en) 2014-04-25 2014-06-11 Ospedale San Raffaele Gene therapy
GB201412494D0 (en) 2014-07-14 2014-08-27 Ospedale San Raffaele And Fond Telethon Vector production
GB201418965D0 (pt) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
GB201608944D0 (en) 2016-05-20 2016-07-06 Ospedale San Raffaele And Fond Telethon Gene Tharapy
GB201706394D0 (en) 2017-04-21 2017-06-07 Ospedale San Raffaele Srl Gene Therapy
DE102017211110A1 (de) 2017-06-30 2019-01-03 Continental Reifen Deutschland Gmbh Verfahren zur Herstellung eines Silans, Verfahren zur Modifizierung einer Kieselsäure mit dem Silan und modifizierte Kieselsäure
GB201807944D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Compositions and methods for haematopoietic stem cell transplantation
GB201807945D0 (en) 2018-05-16 2018-06-27 Ospedale San Raffaele Srl Vector production
CN112601812A (zh) 2018-06-25 2021-04-02 圣拉斐尔医院有限责任公司 基因疗法
JP7633155B2 (ja) 2018-10-11 2025-02-19 オスペダーレ サン ラファエレ エス.アール.エル 人工トランス活性化因子による選択
EP3911312A1 (en) 2019-01-18 2021-11-24 Société des Produits Nestlé S.A. Agents and methods for increasing stem cell function
WO2021094752A1 (en) 2019-11-12 2021-05-20 Oxford Biomedica (Uk) Limited Production system
US20240052366A1 (en) 2020-02-13 2024-02-15 Oxford Biomedica (Uk) Limited Production of Lentiviral Vectors
WO2021181108A1 (en) 2020-03-13 2021-09-16 Oxford Biomedica (Uk) Limited Lentiviral vectors
GB202007106D0 (en) 2020-05-14 2020-07-01 Ucl Business Plc Cyclosporine analogues
GB202007199D0 (en) 2020-05-15 2020-07-01 Oxford Biomedica Ltd Viral vector production
US20230365933A1 (en) 2020-09-28 2023-11-16 Societe Des Produits Nestle S.A. Compositions and methods for increasing stem cell function
EP4217471A1 (en) 2020-09-28 2023-08-02 Société des Produits Nestlé S.A. Compositions and methods for increasing stem cell function
GB202017725D0 (en) 2020-11-10 2020-12-23 Oxford Biomedica Ltd Method
US20240139319A1 (en) 2021-02-01 2024-05-02 Epsilen Bio S.R.L Gene silencing
AU2021202658A1 (en) 2021-04-28 2022-11-17 Fondazione Telethon Gene therapy
CN117202903A (zh) 2021-05-05 2023-12-08 雀巢产品有限公司 用于增加干细胞功能的尿石素
GB202114532D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral Vectors
GB202114530D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Retroviral vectors
GB202114534D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Novel viral regulatory elements
GB202114528D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114529D0 (en) 2021-10-12 2021-11-24 Oxford Biomedica Ltd Lentiviral vectors
GB202114972D0 (en) 2021-10-19 2021-12-01 Ospedale San Raffaele Srl Gene therapy
GB202117844D0 (en) 2021-12-09 2022-01-26 Oxford Biomedica Ltd Purification method
WO2023209223A1 (en) 2022-04-28 2023-11-02 Ospedale San Raffaele S.R.L. Methods for haematopoietic stem cell transplantation
GB202206346D0 (en) 2022-04-29 2022-06-15 Ospedale San Raffaele Srl Gene therapy
GB202209098D0 (en) 2022-06-21 2022-08-10 Ucl Business Ltd Cyclosporine analogues
GB202211935D0 (en) 2022-08-16 2022-09-28 Oxford Biomedica Ltd envelope proteins
EP4602153A1 (en) 2022-10-11 2025-08-20 Fondazione Telethon ETS 3d cell culture methods
IT202300011790A1 (it) 2023-06-08 2024-12-08 Fond Telethon Ets Protocolli di manipolazione genica in cellule immunitarie

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4098824A (en) * 1975-10-02 1978-07-04 Laboratoire L. Lafon Benzhydrylsulphinyl derivatives
DE2804576A1 (de) * 1977-02-15 1978-08-17 Lafon Labor Phenylamidin-derivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen
JP3348725B2 (ja) * 1992-04-07 2002-11-20 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド ヒドロキサム酸ベースのコラゲナーゼとサイトカイン阻害剤
GB9404046D0 (en) * 1994-03-03 1994-04-20 Smithkline Beecham Corp Novel compounds
WO1996035687A1 (en) * 1995-05-10 1996-11-14 Chiroscience Limited Peptidyl compounds and their therapeutic use
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
ATE225343T1 (de) * 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
WO1997024117A1 (en) * 1996-01-02 1997-07-10 Rhone-Poulenc Rorer Pharmaceuticals Inc. Substituted (aryl, heteroaryl, arylmethyl or heteroarylmethyl) hydroxamic acid compounds
WO1998013340A1 (en) * 1996-09-27 1998-04-02 Pharmacia & Upjohn Company β-SULFONYL HYDROXAMIC ACIDS AS MATRIX METALLOPROTEINASES INHIBITORS
WO1998039316A1 (en) * 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds

Also Published As

Publication number Publication date
PL193829B1 (pl) 2007-03-30
ATE266000T1 (de) 2004-05-15
AU3856497A (en) 1998-02-25
PL331598A1 (en) 1999-08-02
DE69729007D1 (de) 2004-06-09
CZ297278B6 (cs) 2006-10-11
CZ36899A3 (cs) 1999-07-14
WO1998005635A1 (en) 1998-02-12
US6118001A (en) 2000-09-12
CN1227540A (zh) 1999-09-01
PT968182E (pt) 2004-08-31
CA2263154A1 (en) 1998-02-12
DE69729007T2 (de) 2005-04-07
ES2217425T3 (es) 2004-11-01
NO314452B1 (no) 2003-03-24
EP0968182A1 (en) 2000-01-05
AU730464B2 (en) 2001-03-08
EP0968182B1 (en) 2004-05-06
JP2000517297A (ja) 2000-12-26
NO990543D0 (no) 1999-02-05
KR20000029858A (ko) 2000-05-25
DK0968182T3 (da) 2004-08-16
NO990543L (no) 1999-04-06

Similar Documents

Publication Publication Date Title
BR9711027A (pt) Derivados de cido hidrox mico e carboxilico tendo atividade inibora de mmp e tnf
BR9908280A (pt) Inibidores de enzimas de fosfolipase
PL331369A1 (en) Thiosulphonic metaloprotease inhibitors
PT1109787E (pt) Arilpiperazinas e sua utilizacao como inibidores de metaloproteinases
ATE214928T1 (de) Thrombininhibitoren
NZ304689A (en) Lactam-containing hydroxamic acid derivatives and use as matrix metalloprotease (mmp) inhibitors
BR9814147A (pt) "derivados de ácido carboxìlico e hidroxâmico tendo atividade inibitória de mmp e tnf"
EA200100804A1 (ru) Сульфоароматические производные гидроксамовой кислоты как ингибиторы металлопротеаз
NZ330860A (en) Method of inhibiting photoaging of skin
ES2191830T3 (es) Inhibidores de trombina.
NO983240L (no) FremgangsmÕte for analyse av korrosjon, og for forhindring av korrosjon
EE200000093A (et) Agrekanaasi ja maatriksmetalloproteinaaside uudsed inhibiitorid artriidi käitlemiseks
TR199802638T2 (xx) Kanser tedavisinde naaladase inhibit�rleri kullan�m�.
WO2000075106A3 (en) Matrix metalloproteinase inhibitors and method of using same
BR0011801A (pt) Inibidores de benzamida substituìda para 3c protease de rinovìrus
DE69625230D1 (de) Thrombininhibitoren
DE69608683D1 (de) Analytisches und therapeutisches mittel
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline
DE69821228D1 (de) Selektive mmp inhibitoren mit verringerten nebenwirkungen
BR9803717A (pt) ácidos indol-2-carbocìlicos substituìdos como inibidores de glucosil transferase.
FR2772233B1 (fr) Equipement de salle de traite des animaux et notamment des ovins ou des caprins
ZA9810359B (en) Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity.
ZA9810360B (en) Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity.
NZ511423A (en) Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
GB9802073D0 (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.